Institutes outside Greece
An investigation into the association between asthma, osteoporosis, and fractures using electronic health records
Abstract
dc:descriptionBackground: Asthma is one of the most common chronic medical conditions; however, little is known about patients’ bone health. Methods: Four observational studies were conducted to investigate (i) the incidence of osteoporosis and fragility fractures in people with asthma compared to the general population, (ii) the risk of osteoporosis and fragility fractures due to corticosteroids in asthma, (iii) the prescribing patterns of oral corticosteroids and bisphosphonates as well as the factors associated with their prescribing, and (iv) the risk of subtrochanteric (ST) and femoral shaft (FS) fractures due to bisphosphonates in asthma. Analyses relied on data from the Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES). OpenPrescribing.net was also used to extract prescribing data to answer the 3rd objective. A systematic review and a series of meta-analyses were also performed assessing the current evidence of the impact of corticosteroids on bone health in patients with asthma. Results: Analysis of incidence showed that patients with asthma had a higher risk of osteoporosis (adjusted hazard ratio (aHR) 1.18, 95% CI 1.13 to 1.23) and were 12% (aHR 1.12, 95% CI 1.07 to 1.16) more likely to sustain fragility fractures than the general population. Age modified the effect of asthma on osteoporosis and fragility fractures, such that the effect was stronger in younger people (pinteraction<0.0001). The vertebra (aHR 1.40, 95% CI 1.33–1.48) and forearm/wrist (aHR 1.27, 95% CI 1.22–1.32) were the sites linked with a significant risk. The study of corticosteroids effect on bone health found a dose–response relationship between both cumulative dose and number of oral (OCS) and inhaled (ICS) corticosteroids prescriptions and risk of osteoporosis or fragility fractures. After adjusting for confounders, people receiving more OCS prescriptions (≥9 vs 0) had a 4.50 (95% CI 3.21 to 6.11) and 2.16 (95% CI 1.56 to 3.32) increased odds of osteoporosis and fragility fractures, respectively. For ICS (≥11 vs 0) the odds were 1.60 (95% CI 1.22 to 2.10) and 1.31 (95% CI 1.02 to 1.68). The cumulative dose had a similar impact, with those receiving more OCS or ICS being at greater risk. Our meta-analysis confirmed the above results. There was no effect of ICS on bone loss at the spine and the femoral neck in asthma. However, people with asthma receiving OCS were at greater risk of osteoporosis than nonexposed people with asthma (pooled HR = 1.76; 95%CI: 1.48 to 2.09; 2=68%). Similarly, higher ICS exposure was associated with higher odds of osteoporosis (OR=1.20; 95%CI: 1.08 to 1.42) and fractures (pooled OR=1.19; 95%CI: 1.05 to 1.35; 2=0%) when comparing people with asthma receiving ICS and not. When the prescribing of bisphosphonates and OCS was examined, although OCS use was positively associated with bisphosphonates prescribing, variation among practices and Clinical Commissioning Groups (CCG) existed. Of the patients with asthma who sustained a ST/FS fracture, 40.3% had received bisphosphonates as compared with 14.2% of the controls, corresponding to an aOR of 4.42 (95%CI, 2.98 to 8.53). The duration of use influenced the risk with long-term users to be at a greater risk (> 5 yrs. vs no exposure; aOR= 7.67; 95%CI, 1.75 to 33.91). Drug withdrawal was associated with diminished odds of ST/FS fractures. Conclusions: These findings have important implications for clinical practice, health policy and future research. Most importantly, results highlight the need to develop an asthma-specific bone protection guidance to ensure safer asthma management, reducing bone comorbidities and improving patients’ quality of life.
Degree
thesis:*- Grantor dc:publisher
- Institutes outside Greece
- Year dc:date
- 2021
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Chalitsios, Christos
- Χαλίτσιος, Χρήστος
Subjects
dc:subject × 20- 'Ασθμα
- Οστεοπόρωση
- Κάταγμα
- Γλυκοκορτικοστεροειδή
- Μεγάλα δεδομένα (BigData)
- Επιδημιολογία
- Asthma
- Osteoporosis
- Fractures
- Glucocorticoids
- Big data
- Epidemiology
- Επιστήμες Υγείας
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Πνευμονολογία και Αναπνευστικές παθήσεις
- Health Sciences
- Medical and Health Sciences
- Clinical Medicine
- Pulmonary and Respiratory Medicine
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/58606